Report Detail

Pharmaceuticals & Healthcare Dental Pain - Pipeline Review, H2 2017

  • RnM1361632
  • |
  • 29 December, 2017
  • |
  • Global
  • |
  • 34 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Dental Pain - Pipeline Review, H2 2017

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Dental Pain - Overview

              Dental Pain - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Dental Pain - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Dental Pain - Companies Involved in Therapeutics Development

                                  Laboratorios Del Dr Esteve SA

                                    Pacira Pharmaceuticals Inc

                                      Teva Pharmaceutical Industries Ltd

                                        Dental Pain - Drug Profiles

                                          (celecoxib + tramadol hydrochloride) - Drug Profile

                                            Product Description

                                              Mechanism Of Action

                                                R&D Progress

                                                  A-100 - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          AFAP-3 - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  bupivacaine ER - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          funapide - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  Dental Pain - Dormant Projects

                                                                                    Dental Pain - Discontinued Products

                                                                                      Dental Pain - Product Development Milestones

                                                                                        Featured News & Press Releases

                                                                                          Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac

                                                                                            Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting

                                                                                              Appendix

                                                                                                Methodology

                                                                                                  Coverage

                                                                                                    Secondary Research

                                                                                                      Primary Research

                                                                                                        Expert Panel Validation

                                                                                                          Contact Us

                                                                                                            Disclaimer

                                                                                                            Dental Pain - Pipeline Review, H2 2017

                                                                                                            Summary

                                                                                                            Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2017, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.

                                                                                                            A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.

                                                                                                            Report Highlights

                                                                                                            Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                            The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

                                                                                                            Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                            Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                            Scope

                                                                                                            - The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).
                                                                                                            - The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                            - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                            - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                            - The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
                                                                                                            - The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                            - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                            - The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)

                                                                                                            Reasons to buy

                                                                                                            - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                            - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                            - Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).
                                                                                                            - Classify potential new clients or partners in the target demographic.
                                                                                                            - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                            - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                            - Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
                                                                                                            - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                            - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                            Purchase this Report

                                                                                                            $2,000.00
                                                                                                            $4,000.00
                                                                                                            $6,000.00
                                                                                                            1,602.69
                                                                                                            3,205.38
                                                                                                            4,808.07
                                                                                                            1,783.25
                                                                                                            3,566.51
                                                                                                            5,349.76
                                                                                                            215,720.00
                                                                                                            431,440.00
                                                                                                            647,160.00
                                                                                                            137,792.80
                                                                                                            275,585.60
                                                                                                            413,378.40
                                                                                                            Credit card Logo

                                                                                                            Related Reports


                                                                                                            Reason to Buy

                                                                                                            Request for Sample of this report